CRSP - Crispr Therapeutics AG - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CRSP is currently covered by 23 analysts with an average price target of $62.47. This is a potential upside of $26.16 (72.05%) from yesterday's end of day stock price of $36.31.

Crispr Therapeutics AG's activity chart (see below) currently has 224 price targets and 222 ratings on display. The stock rating distribution of CRSP is 9.88% SELL, 28.4% HOLD and 61.73% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 56.4% with an average time for these price targets to be met of 93.63 days.

Highest price target for CRSP is $105, Lowest price target is $32, average price target is $73.35.

Most recent stock forecast was given by GENA WANG from BARCLAYS on 09-May-2025. First documented stock forecast 13-Nov-2016.

Currently out of the existing stock ratings of CRSP, 8 are a SELL (9.88%), 23 are a HOLD (28.4%), 50 are a BUY (61.73%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$42

$6.38 (17.91%)

$56

7 days ago
(09-May-2025)

10/17 (58.82%)

$6.38 (17.91%)

101

Hold

$47

$11.38 (31.95%)

$57

8 days ago
(08-May-2025)

4/7 (57.14%)

$10.86 (30.05%)

103

Buy

$81

$45.38 (127.40%)

$84

9 days ago
(07-May-2025)

8/20 (40%)

$46.75 (136.50%)

214

Buy

$82

$46.38 (130.21%)

$84

9 days ago
(07-May-2025)

3/14 (21.43%)

$47.75 (139.42%)

27

Buy

$82

$46.38 (130.21%)

$84

2 months 28 days ago
(17-Feb-2025)

11/18 (61.11%)

$32.28 (64.92%)

196

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CRSP (Crispr Therapeutics AG) average time for price targets to be met?

On average it took 93.63 days on average for the stock forecasts to be realized with a an average price target met ratio 56.4

Which analyst has the current highest performing score on CRSP (Crispr Therapeutics AG) with a proven track record?

EDWARD TENTHOFF

Which analyst has the most public recommendations on CRSP (Crispr Therapeutics AG)?

Edward Tenthoff works at PIPER SANDLER and has 5 price targets and 4 ratings on CRSP

Which analyst is the currently most bullish on CRSP (Crispr Therapeutics AG)?

Maury Raycroft with highest potential upside - $126.61

Which analyst is the currently most reserved on CRSP (Crispr Therapeutics AG)?

Tyler Van Buren with lowest potential downside - -$5.62

Crispr Therapeutics AG in the News

CRISPR Therapeutics (NasdaqGM:CRSP) Q1 2025 Revenue Increases 71% to US$1 Million

CRISPR Therapeutics recently announced its Q1 2025 earnings, reporting a 71% year-over-year revenue increase to $0.9 million, but also a wider net loss of $136 million. The basic and diluted loss per share rose to $1.58. Despite these mixed financial results, the company’s stock rose 5.8% over the past month, aligning with the broader market’s...

Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock’s price, do they really matter? Let’s take a look at what these Wall Street heavyweights have to...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?